NEW YORK (GenomeWeb News) – Allegro Diagnostics has won up to $2.8 million in funding from the National Cancer Institute for clinical studies of its BronchoGen, a molecular diagnostic test for early-stage lung cancer.

The company said today that it will use the Phase I and II Fast Track Small Business Innovation Research funding for a study that will enroll up to 800 patients in 12 sites in the US.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Even when given the option, not too many authors choose double-blinded peer-review for their manuscripts, ScienceInsider reports.

In PNAS this week: transcriptional read-through in stressed cells, genome stability role for the epigenetic regulator CTCF, and more.

The Save the Redwoods League is teaming with researchers to sequence the genomes of the coast redwood and giant sequoia.

Two researchers have found that behavioral genetic defenses in criminal cases don't tend to affect outcomes, according to Popular Science.